AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: AZD9977

First Posted Date: 2019-01-14

Last Posted Date: 2019-05-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 28

Registration Number: NCT03801967

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Other: Placebo
Drug: Durvalumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Gemcitabine
Procedure: Surgery

First Posted Date: 2019-01-11

Last Posted Date: 2025-01-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 825

Registration Number: NCT03800134

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

Completed

Conditions: NSCLC

First Posted Date: 2019-01-10

Last Posted Date: 2024-10-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 1156

Registration Number: NCT03798535

Locations: 🇬🇧
Research Site, Stoke on Trent, United Kingdom

Benralizumab Pregnancy Exposure Study

Terminated

Conditions: Asthma

Interventions: Drug: Benralizumab-exposure
Drug: Exposure to other asthma medications

First Posted Date: 2019-01-07

Last Posted Date: 2024-11-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 299

Registration Number: NCT03794999

Locations: 🇺🇸
Research Site, San Diego, California, United States

Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

Completed

Conditions: Urothelial Carcinoma

First Posted Date: 2018-12-28

Last Posted Date: 2024-02-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 181

Registration Number: NCT03788746

Locations: 🇺🇸
Research Site, Wenatchee, Washington, United States

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Phase 2

Active, not recruiting

Conditions: Carcinoma

Interventions: Drug: savolitinib
Drug: osimertinib
Drug: placebo

First Posted Date: 2018-12-19

Last Posted Date: 2025-05-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 367

Registration Number: NCT03778229

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

Phase 3

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Other: Placebo
Drug: Durvalumab
Procedure: Transarterial Chemoembolization (TACE)
Drug: Bevacizumab

First Posted Date: 2018-12-19

Last Posted Date: 2025-04-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 724

Registration Number: NCT03778957

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer NSCLC

Interventions: Drug: Durvalumab
Drug: Olaparib
Drug: Placebo for Olaparib
Drug: Nab-paclitaxel+carboplatin
Drug: Gemcitabine+carboplatin
Drug: Pemetrexed+carboplatin
Drug: Gemcitabine+cisplatin
Drug: Pemetrexed+cisplatin

First Posted Date: 2018-12-14

Last Posted Date: 2025-03-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 401

Registration Number: NCT03775486

Locations: 🇬🇧
Research Site, Hull, United Kingdom

A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
Drug: Treatment B (Budesonide metered dose inhaler)
Drug: Treatment C (Albuterol Sulfate metered dose inhaler)

First Posted Date: 2018-12-11

Last Posted Date: 2019-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 91

Registration Number: NCT03772223

Locations: 🇬🇧
Research Site, London, United Kingdom

A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: AZD0449
Drug: Placebo

First Posted Date: 2018-12-06

Last Posted Date: 2024-08-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 131

Registration Number: NCT03766399

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy